Manufacturing

Humanigen gains BARDA access to produce lenzilumab for treating Covid-19

Humanigen has announced an expansion to the Cooperative Research and Development Agreement (CRADA) with the Department of Defense Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND).

Akron Biotech to exclusively manufacture Human AB Serum for Octapharma

Akron Biotechnology (Akron Biotech) has signed an exclusive global agreement with Swiss-based Octapharma, to manufacture virally inactivated Human AB Serum for the cell therapy market.

Rocket Pharmaceuticals announces buildout of R&D and manufacturing facility to support development of gene therapy pipeline

Rocket Pharmaceuticals, a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, today announces the Company’s plans for the buildout of its new Research and Development (R&D) and Chemistry, Manufacturing and Controls (CMC) operation which will also serve as the Company’s new headquarters in Cranbury, New Jersey.

LakePharma to manufacture Akston Biosciences’ Covid-19 vaccine

Akston Biosciences has entered into a strategic partnership with US-based contract research, development, and manufacturing organisation (CRDMO) LakePharma to manufacture second-generation Covid-19 vaccine.

EIB launches €50m Africa pharmaceutical manufacturing initiative

The European Investment Bank launched the first ever scheme to strengthen local production of Active Pharmaceutical Ingredients in Africa and scale up drug manufacturing essential to improve public health.

Thermo Fisher Scientific further expands global footprint for drug product development and commercial manufacturing

Thermo Fisher Scientific, the world leader in serving science, announced it will further expand its footprint in North America and Europe for sterile drug product development and commercial manufacturing of critical medicines, therapies and vaccines.

BioCryst announces $325m of funding from Royalty Pharma and Athyrium Capital Management

BioCryst Pharmaceuticals, Royalty Pharma, and Athyrium Capital Management, announced transactions totaling $325 million in funding for BioCryst, with $250 million available at closing, to support the launch of ORLADEYO (berotralstat) in hereditary angioedema (HAE) and the development of its oral Factor D inhibitor, BCX9930.

Piramal Pharma Solutions invests $32m to expand Riverview Michigan facility

Piramal Pharma Limited's Pharma Solutions business, a leading Contract Development and Manufacturing Organization (CDMO) announced plans to expand its facility in Michigan with additional capacity and new capabilities for the development and manufacturing of Active Pharmaceutical Ingredients (APIs).

SAB Biotherapeutics awarded $57.5m from BARDA and US Department of Defense for SAB-185

SAB Biotherapeutics (SAB) as part of Operation Warp Speed, the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services, and the Department of Defense Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) have awarded SAB $57.5 million in expanded scope for its DiversitAb Rapid Response Antibody Program contract for the manufacturing of SAB-185, the company’s clinical stage therapeutic candidate for COVID-19.